PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17673547-11 2007 These results confirmed the importance of COX-2/PGE2 in the healing mechanism of gastric ulcers and further suggested that the healing-promoting action of PGE2 is mediated by the activation of EP4 receptors and is associated with VEGF expression. Dinoprostone 155-159 vascular endothelial growth factor A Mus musculus 230-234 18567804-6 2008 In addition, these inhibitors attenuated the PGE2-induced proliferation, nuclear factor-kappa B, activator protein-1 (AP-1), and CREB binding to the promoter regions of the cyclin D1 and vascular endothelial growth factor (VEGF) genes and expression of cyclin D1 and VEGF in primary mouse keratinocytes. Dinoprostone 45-49 vascular endothelial growth factor A Mus musculus 187-221 18567804-6 2008 In addition, these inhibitors attenuated the PGE2-induced proliferation, nuclear factor-kappa B, activator protein-1 (AP-1), and CREB binding to the promoter regions of the cyclin D1 and vascular endothelial growth factor (VEGF) genes and expression of cyclin D1 and VEGF in primary mouse keratinocytes. Dinoprostone 45-49 vascular endothelial growth factor A Mus musculus 223-227 18567804-6 2008 In addition, these inhibitors attenuated the PGE2-induced proliferation, nuclear factor-kappa B, activator protein-1 (AP-1), and CREB binding to the promoter regions of the cyclin D1 and vascular endothelial growth factor (VEGF) genes and expression of cyclin D1 and VEGF in primary mouse keratinocytes. Dinoprostone 45-49 vascular endothelial growth factor A Mus musculus 267-271 18567804-7 2008 Similarly, in vivo, we found that WT mice treated with PGE2 and untreated cyclooxygenase-2-overexpressing transgenic mice had higher levels of cell proliferation and expression of cyclin D1 and VEGF, as well as higher levels of activated EGFR, nuclear factor-kappa B, AP-1, and CREB, than vehicle-treated WT mice. Dinoprostone 55-59 vascular endothelial growth factor A Mus musculus 194-198 15302995-9 2004 In turn, LM2 cells angiogenic response could be due in fact to PGE2-induced VEGF liberation that stimulated neoangiogenesis at very low levels of NO. Dinoprostone 63-67 vascular endothelial growth factor A Mus musculus 76-80 12772586-2 2003 In culture of the minced granulation tissue, PGE2 induced VEGF production in a concentration-dependent manner. Dinoprostone 45-49 vascular endothelial growth factor A Mus musculus 58-62 12772586-9 2003 These findings suggest that PGE2 and histamine augment angiogenesis in the inflammatory granulation tissue by inducing VEGF production, and histamine induces VEGF production possibly through the H2 receptor--cAMP--protein kinase A pathway. Dinoprostone 28-32 vascular endothelial growth factor A Mus musculus 119-123 11688844-7 2001 In vitro, PGE2 induces VEGE Supernatants of cultured cells from breast, prostate, and squamous cell cancers contain angiogenic proteins such as COX-2 and VEGF that induce in vitro angiogenesis. Dinoprostone 10-14 vascular endothelial growth factor A Mus musculus 154-158 9349634-12 1997 These results suggest that increased vascular permeability induced by VEGF is mediated by local production of NO and arachidonic acid metabolites other than PGE2, which are most probably produced by inducible NO synthase and cyclooxygenase-2, respectively. Dinoprostone 157-161 vascular endothelial growth factor A Mus musculus 70-74 11728162-0 2001 Prostaglandin E(2) modulation of vascular endothelial growth factor production in murine macrophages. Dinoprostone 0-17 vascular endothelial growth factor A Mus musculus 33-67 21328462-5 2011 In addition, we found that vitamin C suppressed the expression of cyclooxygenase (COX)-2 and that decreased VEGF production by vitamin C was also restored by the administration of prostaglandin E2 which is a product of COX-2. Dinoprostone 180-196 vascular endothelial growth factor A Mus musculus 108-112 34035084-0 2021 Intravital imaging identifies the VEGF-TXA2 axis as a critical promoter of PGE2 secretion from tumor cells and immune evasion. Dinoprostone 75-79 vascular endothelial growth factor A Mus musculus 34-43 34035084-3 2021 Here, we show that VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in PGE2 secretion and subsequent immune evasion in the early stages of tumorigenesis. Dinoprostone 123-127 vascular endothelial growth factor A Mus musculus 19-23 34035084-8 2021 Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues. Dinoprostone 170-174 vascular endothelial growth factor A Mus musculus 26-60 34035084-8 2021 Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues. Dinoprostone 170-174 vascular endothelial growth factor A Mus musculus 62-66 34035084-8 2021 Notably, treatment with a vascular endothelial growth factor (VEGF) receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues. Dinoprostone 170-174 vascular endothelial growth factor A Mus musculus 100-104 34035084-9 2021 These results identify the VEGF-TXA2 axis as a critical promoter of PGE2-dependent tumor immune evasion, providing a molecular basis underlying the immunomodulatory effect of anti-VEGF therapies. Dinoprostone 68-72 vascular endothelial growth factor A Mus musculus 27-36 34035084-9 2021 These results identify the VEGF-TXA2 axis as a critical promoter of PGE2-dependent tumor immune evasion, providing a molecular basis underlying the immunomodulatory effect of anti-VEGF therapies. Dinoprostone 68-72 vascular endothelial growth factor A Mus musculus 27-31 29963167-6 2018 The effect of exogenous PGE2 on the downregulation of VEGF by Celebrex was also assessed. Dinoprostone 24-28 vascular endothelial growth factor A Mus musculus 54-58 29963167-11 2018 The in vitro study indicated that Celebrex suppressed the expression of VEGF and PGE2 in PC-3 cells in a dose- and time-dependent manner, while exogenous PGE2 rescued the expression of VEGF, which was suppressed by Celebrex, in a dose-dependent manner. Dinoprostone 154-158 vascular endothelial growth factor A Mus musculus 185-189 29963167-13 2018 These data provide evidence that PGE2 may be an important mediator between COX-2 and VEGF expression in the process of angiogenesis in pancreatic cancer. Dinoprostone 33-37 vascular endothelial growth factor A Mus musculus 85-89 25936351-11 2015 Our data suggest that GPR91 modulates the succinate-induced release of VEGF through the MAPK/COX-2/PGE2 signaling pathway. Dinoprostone 99-103 vascular endothelial growth factor A Mus musculus 71-75 25625500-11 2015 In vitro, the protein expression levels of VEGF produced by the PGE2-treated cells were significantly increased in a concentration-dependent manner. Dinoprostone 64-68 vascular endothelial growth factor A Mus musculus 43-47 25625500-14 2015 These results demonstrated that PGE2 may regulate the release of VEGF by MPVECs through the EP2 receptor pathway and thereby promoted pulmonary angiogenesis and breast cancer metastasis in a mouse model. Dinoprostone 32-36 vascular endothelial growth factor A Mus musculus 65-69 25894216-8 2015 Reduction in prostaglandin E2 synthesis also led to reduced level of VEGF in plasma. Dinoprostone 13-29 vascular endothelial growth factor A Mus musculus 69-73 23938462-5 2014 The cascade involved prostaglandin E2 (PGE2) production from melanoma induced by IL-18-dependent tumor necrosis factor-alpha (TNFalpha); next, PGE2-induced IL-1beta via vascular endothelial growth factor (VEGF) secretion, which in turn induced VLA-4 activation via cyclooxygenase 2-dependent H2O2. Dinoprostone 21-37 vascular endothelial growth factor A Mus musculus 205-209 25333935-0 2014 Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2. Dinoprostone 106-122 vascular endothelial growth factor A Mus musculus 0-34 25333935-5 2014 Moreover, vascular endothelial growth factor (VEGF) induced prostaglandin E2 (PGE2) production in mouse pulmonary microvascular endothelial cells (MPVECs) and enhanced the adhesion of 4T1 cells. Dinoprostone 60-76 vascular endothelial growth factor A Mus musculus 10-44 25333935-5 2014 Moreover, vascular endothelial growth factor (VEGF) induced prostaglandin E2 (PGE2) production in mouse pulmonary microvascular endothelial cells (MPVECs) and enhanced the adhesion of 4T1 cells. Dinoprostone 60-76 vascular endothelial growth factor A Mus musculus 46-50 25333935-5 2014 Moreover, vascular endothelial growth factor (VEGF) induced prostaglandin E2 (PGE2) production in mouse pulmonary microvascular endothelial cells (MPVECs) and enhanced the adhesion of 4T1 cells. Dinoprostone 78-82 vascular endothelial growth factor A Mus musculus 10-44 25333935-5 2014 Moreover, vascular endothelial growth factor (VEGF) induced prostaglandin E2 (PGE2) production in mouse pulmonary microvascular endothelial cells (MPVECs) and enhanced the adhesion of 4T1 cells. Dinoprostone 78-82 vascular endothelial growth factor A Mus musculus 46-50 25333935-9 2014 Primary tumor-derived VEGF might thus be a crucial factor responsible for the formation of the pre-metastatic niche by inducing PGE2 production. Dinoprostone 128-132 vascular endothelial growth factor A Mus musculus 22-26 23938462-5 2014 The cascade involved prostaglandin E2 (PGE2) production from melanoma induced by IL-18-dependent tumor necrosis factor-alpha (TNFalpha); next, PGE2-induced IL-1beta via vascular endothelial growth factor (VEGF) secretion, which in turn induced VLA-4 activation via cyclooxygenase 2-dependent H2O2. Dinoprostone 143-147 vascular endothelial growth factor A Mus musculus 169-203 23938462-5 2014 The cascade involved prostaglandin E2 (PGE2) production from melanoma induced by IL-18-dependent tumor necrosis factor-alpha (TNFalpha); next, PGE2-induced IL-1beta via vascular endothelial growth factor (VEGF) secretion, which in turn induced VLA-4 activation via cyclooxygenase 2-dependent H2O2. Dinoprostone 143-147 vascular endothelial growth factor A Mus musculus 205-209 20145550-0 2010 Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. Dinoprostone 105-109 vascular endothelial growth factor A Mus musculus 19-23 20145550-9 2010 These studies demonstrate that tumor-derived VEGF induces endothelial cells to upregulate production of PGE2 which, in turn, leads to suppression of T-cell functions. Dinoprostone 104-108 vascular endothelial growth factor A Mus musculus 45-49 19187602-10 2008 Furthermore, exogenous PGE2 increased VEGF production in bEnd.3 cells, and AH6809 blocked this effect. Dinoprostone 23-27 vascular endothelial growth factor A Mus musculus 38-42 19187602-11 2008 CONCLUSION: bFGF increases VEGF production in an autocrine manner by increasing COX-2-generated PGE2 in cMVECs and subsequently stimulates MVEC proliferation and angiogenesis. Dinoprostone 96-100 vascular endothelial growth factor A Mus musculus 27-31 19765669-5 2009 Intraperitoneal ONO-AE1-259 and PGE2 each increased the concentration of vascular endothelial growth factor (VEGF) and the number of endothelial progenitor cells (EPCs) in circulating blood. Dinoprostone 32-36 vascular endothelial growth factor A Mus musculus 73-107 19765669-5 2009 Intraperitoneal ONO-AE1-259 and PGE2 each increased the concentration of vascular endothelial growth factor (VEGF) and the number of endothelial progenitor cells (EPCs) in circulating blood. Dinoprostone 32-36 vascular endothelial growth factor A Mus musculus 109-113